917772-60-2

Basic information

• Product Name: 3,4-Pyrrolidinedicarboxylic acid, 3-(4-bromo-2-thienyl)-1-(phenylmethyl)-
• CAS NO: 917772-60-2
• Molecular Formula: C17H16BrNO4S
• Molecular Weight: 410.288
• Mol File: 917772-60-2.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 3,4-Pyrrolidinedicarboxylic acid, 3-(4-bromo-2-thienyl)-1-(phenylmethyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 3,4-Pyrrolidinedicarboxylic acid, 3-(4-bromo-2-thienyl)-1-(phenylmethyl)-(917772-60-2)
• EPA Substance Registry System: 3,4-Pyrrolidinedicarboxylic acid, 3-(4-bromo-2-thienyl)-1-(phenylmethyl)-(917772-60-2)

Safety Data

• Hazardous Substances Data: 917772-60-2(Hazardous Substances Data)

Upstream product

• 917772-58-8 C₈H₃BrO₃S 
• 917772-59-9 C₈H₅BrO₄S 
• 93102-05-7 N-benzyl-N-(methoxymethyl)-N-[(trimethylsilyl)methyl]amine 
• 1192479-38-1 C₈H₅BrO₄S 
• 917772-57-7 C₈H₄BrNO₂S 
• 79757-77-0 (4-bromothiophen-2-yl)methanol 
• 160005-43-6 2-(4-bromothiophen-2-yl)acetonitrile 
• 170859-70-8 4-bromo-2-(chloromethyl)thiophene 
• 18791-75-8 4-Bromothiophen-2-aldehyde 

Downstream Products

• 1192479-39-2 C₁₈H₁₈BrNO₄S*ClH 
• 917772-61-3 C₁₈H₁₈BrNO₄S 
• 1400771-98-3 C₂₃H₂₁N₇OS 
• 1400771-97-2 C₂₂H₁₈ClN₇OS 
• 1400771-96-1 C₂₂H₁₈FN₇OS 
• 1400771-95-0 C₂₂H₁₉N₇OS 
• 1400771-94-9 C₂₄H₁₉F₃N₆OS 

Relevant articles and documents

Design and validation of bicyclic iminopyrimidinones as beta amyloid cleaving enzyme-1 (BACE1) inhibitors: Conformational constraint to favor a bioactive conformation

On the basis of our observation that the biaryl substituent of iminopyrimidinone 7 must be in a pseudoaxial conformation to occupy the contiguous S1-S3 subsites of BACE1, we have designed a novel fused bicyclic iminopyrimidinone scaffold intended to favor this bioactive conformation. Strategic incorporation of a nitrogen atom in the new constrained ring allowed us to develop SAR around the S2′ binding pocket and ultimately resulted in analogues with low nanomolar potency for BACE1. In particular, optimization of the prime side substituent led to major improvements in potency by displacement of two conserved water molecules from a region near S2′. Further optimization of the pharmacokinetic properties of this fused pyrrolidine series, in conjunction with facile access to a rat pharmacodynamic model, led to identification of compound 43, which is an orally active, brain penetrant inhibitor that reduces Aβ40 in the plasma, CSF, and cortex of rats in a dose-dependent manner.

ASPARTYL PROTEASE INHIBITORS

Disclosed are compounds of the formula (I) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein j, k, U, W, R, R1, R2, R3, R4, R6, R7 and R7a are as described above in the specification. Also disclosed is the method of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases. Also disclosed are methods of treating cognitive or neurodegenerative diseases using the compounds of formula (I) in combination with a cholinesterase inhibitor or a muscarinic m1 agonist or m2 antagonist.